Skip to main content

Table 2 Group comparison of EEG characteristics and NBM volume

From: EEG alpha reactivity and cholinergic system integrity in Lewy body dementia and Alzheimer’s disease

 

HC

AD

LBD

Group comparison

Individual alpha peak

8.8 [8.4, 9.2]

7.4 [6.3, 8.4]

6.4 [6.1, 6.7]

F2 = 42.1, p < 0.001a

p (HC, AD) = 0.004

p (HC, LBD) < 0.001

p (AD, LBD) = 0.092

Alpha reactivity

0.56 [0.50, 0.63]

0.24 [0.12, 0.34]

0.08 [0.03, 0.14]

F2 = 59.9, p < 0.001b

p (HC, AD) < 0.001

p (HC, LBD) < 0.001

p (AD, LBD) = 0.014

Eyes-closed alpha power

49.1 [41.9, 56.3]

34.4 [27.5, 41.3]

39.7 [35.8, 43.5]

F2 = 7.9, p = 0.019a

p (HC, AD) = 0.018

p (HC, LBD) = 0.25

p (AD, LBD) = 0.56

Eyes-open alpha power

18.9 [16.1, 21.7]

24.2 [19.4, 29.0]

36.7 [32.4, 41.1]

F2 = 35.5, p < 0.001a

p (HC, AD) = 0.25

p (HC, LBD) < 0.001

p (AD, LBD) = 0.005

NBM volume

0.19 [0.18, 0.20]

0.17 [0.16, 0.17]

0.16 [0.15, 0.17]

F2 = 13.3, p < 0.001b

p (HC, AD) = 0.003

p (HC, LBD) < 0.001

p (AD, LBD) = 1.0

  1. Mean [95% confidence interval]. Alpha power and alpha reactivity estimated from electrodes O1, Oz, and O2 using individual alpha peak frequencies. NBM volume normalised to total intracranial volume. Group differences assessed by univariate ANOVA or Kruskal-Wallis ANOVA with post hoc tests corrected for multiple comparisons
  2. AD Alzheimer’s disease, HC healthy controls, LBD Lewy body dementia, NBM nucleus basalis of Meynert
  3. aKruskal-Wallis ANOVA
  4. bUnivariate ANOVA